

Ennio Giulio Favalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7885309/publications.pdf>

Version: 2024-02-01

132
papers

4,387
citations

109137

35
h-index

118652

62
g-index

140
all docs

140
docs citations

140
times ranked

6180
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. <i>Autoimmunity Reviews</i> , 2020, 19, 102523.	2.5	353
2	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1012-1013.	4.6	178
3	Obesity and reduction of the response rate to anti-tumor necrosis factor in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	1.5	170
4	Serious infections during anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	2.5	148
5	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	2.5	146
6	TNF Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	1.8	130
7	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 333-345.	2.9	126
8	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.)	2.5	107
9	Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor blockade. <i>Journal of Autoimmunity</i> , 2008, 31, 175-179.	3.0	102
10	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	2.5	101
11	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 57-70.	2.0	99
12	Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?. <i>Arthritis and Rheumatology</i> , 2020, 72, 1600-1606.	2.9	95
13	Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism. <i>Arthritis and Rheumatology</i> , 2015, 67, 1155-1164.	2.9	94
14	What is the true incidence of COVID-19 in patients with rheumatic diseases?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e18-e18.	0.5	89
15	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1593-1603.	2.0	85
16	Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. <i>Lupus</i> , 2002, 11, 753-755.	0.8	81
17	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 175-180.	2.5	80
18	Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. <i>Journal of Rheumatology</i> , 2020, 47, 1296-1296.	1.0	78

#	ARTICLE	IF	CITATIONS
19	Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 473-516.	1.1	73
20	Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). <i>Rheumatology</i> , 2010, 49, 289-294.	0.9	70
21	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014, 53, 1664-1668.	0.9	70
22	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014, 13, 1102-1108.	2.5	70
23	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016, 68, 432-439.	1.5	69
24	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017, 16, 1185-1195.	2.5	67
25	The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. <i>Journal of Rheumatology</i> , 2017, 44, 279-285.	1.0	66
26	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	2.9	63
27	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	1.6	63
28	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019, 8, 1-12.	1.0	55
29	Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. <i>Immunologic Research</i> , 2015, 61, 24-30.	1.3	51
30	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	2.5	50
31	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
32	Are patients with systemic lupus erythematosus at increased risk for COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e25-e25.	0.5	41
33	Biomarkers in psoriatic arthritis: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 651-660.	1.3	39
34	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019, 79, 1741-1755.	4.9	39
35	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 465-469.	2.5	38
36	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	1.0	37

#	ARTICLE	IF	CITATIONS
37	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 290.	1.6	37
38	Anti-TNF \pm therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. <i>Autoimmunity Reviews</i> , 2009, 8, 260-265.	2.5	35
39	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <i>Pediatric Rheumatology</i> , 2020, 18, 35.	0.9	35
40	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2090604.	1.2	34
41	Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. <i>Arthritis Research and Therapy</i> , 2022, 24, 21.	1.6	34
42	Mavrimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 573-581.	1.9	33
43	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017, 69, 867-874.	1.5	32
44	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017, 36, 1747-1755.	1.0	31
45	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S15-27.	0.4	31
46	Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides. <i>Drug Development Research</i> , 2014, 75, S38-41.	1.4	30
47	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	1.0	28
48	Anti-tumor necrosis factor \pm switching in rheumatoid arthritis and juvenile chronic arthritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 301-302.	6.7	26
49	Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	25
50	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-217251.	0.5	25
51	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	3.0	25
52	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	0.9	24
53	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	24
54	Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 47, 6-16.	2.9	23

#	ARTICLE	IF	CITATIONS
55	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine, 2014, 81, 37-40.	0.8	23
56	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <scp>LORHEN</scp> registry. International Journal of Rheumatic Diseases, 2018, 21, 422-430.	0.9	22
57	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine, 2014, 81, 508-512.	0.8	21
58	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	1.5	20
59	Does polymorphism of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. Autoimmunity Reviews, 2011, 10, 460-463.	2.5	19
60	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	1.0	19
61	Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 9-17.	0.7	18
62	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 211-223.	2.0	17
63	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open, 2020, 6, e001211.	1.8	17
64	Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clinical and Experimental Rheumatology, 2017, 35, 804-809.	0.4	17
65	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine, 2018, 85, 455-459.	0.8	14
66	Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Related Outcome Measures, 2018, Volume 9, 275-284.	0.7	14
67	Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days. Dermatologic Therapy, 2020, 33, e13415.	0.8	14
68	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. Annals of the Rheumatic Diseases, 2021, 80, e75-e75.	0.5	14
69	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine, 2021, 88, 105062.	0.8	14
70	Ultrasonography in the diagnosis and management of patients with inflammatory arthritides. European Journal of Internal Medicine, 2014, 25, 103-111.	1.0	13
71	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Design, Development and Therapy, 2018, Volume 12, 1421-1429.	2.0	13
72	The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmunity Reviews, 2020, 19, 102421.	2.5	13

#	ARTICLE	IF	CITATIONS
73	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	2.5	13
74	Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. <i>Clinica Chimica Acta</i> , 2014, 437, 161-167.	0.5	12
75	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016, 44, 113-118.	0.4	12
76	Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 153-157.	1.0	12
77	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	12
78	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 213-223.	1.2	11
79	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e5-e5.	0.5	11
80	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1969-1978.	2.0	11
81	Structural integrity versus radiographic progression in rheumatoid arthritis: Figure 1. <i>RMD Open</i> , 2015, 1, e000064.	1.8	10
82	How advances in personalized medicine will change rheumatology. <i>Personalized Medicine</i> , 2018, 15, 75-78.	0.8	10
83	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1313-1322.	1.3	10
84	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020, 40, 263-272.	1.5	10
85	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 561-571.	1.3	10
86	The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2018, 148, w14656.	0.8	10
87	Tofacitinib's infectious profile: concerns for clinical practice. <i>Lancet Rheumatology</i> , The, 2020, 2, e65-e67.	2.2	9
88	Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	8
89	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: Data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 730-737.	1.6	8
90	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018, 28, 542-549.	0.9	8

#	ARTICLE	IF	CITATIONS
91	GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?. <i>Lancet Rheumatology, The</i> , 2020, 2, e448-e449.	2.2	8
92	Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors. <i>Annals of Translational Medicine</i> , 2018, 6, S82-S82.	0.7	7
93	Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e55-e55.	0.5	6
94	Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1206-1213.	0.5	6
95	Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1243-1245.	0.5	5
96	Vitamin D and Spondyloarthritis: Review of the Literature. <i>Open Rheumatology Journal</i> , 2018, 12, 214-225.	0.1	5
97	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.4	5
98	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 19-26.	0.4	5
99	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. <i>Journal of Rheumatology</i> , 2017, 44, 262-263.	1.0	4
100	Dr. Favalli, et al reply. <i>Journal of Rheumatology</i> , 2020, 47, 1592-1592.	1.0	4
101	Managing patients with rheumatic conditions during the covid-19 pandemic. <i>BMJ, The</i> , 2020, 369, m1633.	3.0	4
102	Secukinumab in <sc>HLA-B*27</sc> associated uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 388-389.	1.3	4
103	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.3	3
104	Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8490.	1.2	3
105	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. <i>Frontiers in Medicine</i> , 2021, 8, 711875.	1.2	3
106	The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. <i>Frontiers in Medicine</i> , 2022, 9, 850858.	1.2	3
107	Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 799-813.	2.5	3
108	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258.	2.5	2

#	ARTICLE	IF	CITATIONS
109	Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". Journal of the American Academy of Dermatology, 2018, 79, e119-e120.	0.6	2
110	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. Expert Review of Clinical Pharmacology, 2021, 14, 661-670.	1.3	2
111	Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. Clinical and Experimental Rheumatology, 2018, 36, 479-485.	0.4	2
112	AB0225...Clinical outcomes of treatment with golimumab in seropositive and seronegative rheumatoid arthritis patients in real-life settings. data from italian register gisea. , 2018, , .		1
113	SAT0375...MILD COGNITIVE IMPAIRMENT IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS. , 2019, , .		1
114	FRI0404...POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		1
115	Is there really room for anti-rheumatic drugs in the treatment of COVID-19?. Scandinavian Journal of Rheumatology, 2020, 49, 412-413.	0.6	1
116	SAT0132...Comorbidities affect the retention rate but not the clinical response in a cohort of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors.. , 2018, , .		1
117	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. Indian Journal of Rheumatology, 2019, 14, 271.	0.2	1
118	Damage progression in rheumatoid arthritis: the role of biologic agents. Arthritis Research and Therapy, 2012, 14, .	1.6	0
119	Tocilizumab after A First-Line with Anti-Tnf in Rheumatoid Arthritis: A Cost-Consequence Analysis in the Italian Setting. Value in Health, 2017, 20, A533.	0.1	0
120	THU0366...Gastrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register. , 2017, , .		0
121	PARE0018...ENABLING PATIENT-CENTRED CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES. , 2019, , .		0
122	FRI0042...CERTOLIZUMAB PEGOL EFFECTIVENESS IN WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL MULTICENTRE COHORT. , 2019, , .		0
123	AB1368-HPR...ENHANCED ROLE OF NURSES AND OTHER HEALTHCARE PROFESSIONALS (HCPS) IN THE CARE OF RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES. , 2019, , .		0
124	THU0638...CONSIDERATIONS FOR IMPROVING QUALITY OF CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES. , 2019, , .		0
125	FRI0114...Efficacy and retention rate of certolizumab pegol in rheumatoid arthritis: data from a large real-life multicentre retrospective cohort. , 2018, , .		0
126	FRI0143...Influence of low-dose glucocorticoid treatment on persistence on biologic dmards therapy: real-life data from the italian gisea registry. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
127	SAT0223â€¦Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry.. , 2018, , .		0
128	SAT0193â€¦Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		0
129	SAT0327â€¦Baseline characteristics and reasons for apremilast prescription in a large italian cohort of psoriatic arthritis patients. , 2018, , .		0
130	THU0287â€¦The prevalence of remission in a real-life cohort of psoriatic arthritis patients treated with synthetic or biologic disease modifying drugs. , 2018, , .		0
131	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs in Context, 0, 8, 1-12.	1.0	0
132	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Frontiers in Immunology, 0, 13, .	2.2	0